Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. [Review]

MedStar author(s):
Citation: Hematology - Oncology Clinics of North America. 2022 Sep 22PMID: 36154782Department: Hematology & Oncology Fellowship | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:
  • 0889-8588
Name of journal: Hematology/oncology clinics of North AmericaAbstract: Advanced pancreatic cancer remains one of the deadliest malignancies in 2022. Although there has been significant progress in treatment options with improved outcomes in many cancers, this growth has been slow in pancreatic cancer. This article examines specific components of approved first- and second-line therapies for advanced pancreatic cancer treatment and their effectiveness and concludes with a brief exploration of future directions for targeted therapies. Copyright © 2022 Elsevier Inc. All rights reserved.All authors: Khaled A, Noel M, Rehman MFiscal year: FY2023Digital Object Identifier: Date added to catalog: 2022-10-20
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 36154782 Available 36154782

Advanced pancreatic cancer remains one of the deadliest malignancies in 2022. Although there has been significant progress in treatment options with improved outcomes in many cancers, this growth has been slow in pancreatic cancer. This article examines specific components of approved first- and second-line therapies for advanced pancreatic cancer treatment and their effectiveness and concludes with a brief exploration of future directions for targeted therapies. Copyright © 2022 Elsevier Inc. All rights reserved.

English

Powered by Koha